GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more
GeneReach Biotechnology (4171) - Total Liabilities
Latest total liabilities as of September 2025: NT$285.79 Million TWD
Based on the latest financial reports, GeneReach Biotechnology (4171) has total liabilities worth NT$285.79 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneReach Biotechnology - Total Liabilities Trend (2017–2024)
This chart illustrates how GeneReach Biotechnology's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeneReach Biotechnology Competitors by Total Liabilities
The table below lists competitors of GeneReach Biotechnology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SJ Group Co. Ltd
KQ:306040
|
Korea | ₩96.06 Billion |
|
Marvipol S.A.
WAR:MVP
|
Poland | zł655.61 Million |
|
Dolphin Offshore Enterprises (India) Limited
NSE:DOLPHIN
|
India | ₹2.21 Billion |
|
Emperor International Holdings Limited
F:EM3A
|
Germany | €19.52 Billion |
|
Ozerden Plastik Sanayi
IS:OZRDN
|
Turkey | TL52.79 Million |
|
Palisades Goldcorp Ltd.
PINK:PLGDF
|
USA | $68.65 Million |
|
Getchell Gold Corp
OTCQB:GGLDF
|
USA | $453.41K |
|
Menon Bearings Limited
NSE:MENONBE
|
India | ₹852.87 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down GeneReach Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneReach Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneReach Biotechnology (2017–2024)
The table below shows the annual total liabilities of GeneReach Biotechnology from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$341.00 Million | +8.70% |
| 2023-12-31 | NT$313.71 Million | -39.58% |
| 2022-12-31 | NT$519.23 Million | -12.93% |
| 2021-12-31 | NT$596.35 Million | +55.81% |
| 2020-12-31 | NT$382.75 Million | +128.07% |
| 2019-12-31 | NT$167.82 Million | -56.15% |
| 2018-12-31 | NT$382.68 Million | +8.65% |
| 2017-12-31 | NT$352.21 Million | -- |